US Patent 10300055 Treatment of parkinson's disease through ARFGAP1 inhibition
Patent 10300055 was granted and assigned to Dalhousie University on May, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+376 characters)
Article
Patent abstract
Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Carla Zimmerman0
Chris McMaster0
Michel Roberge0
Pak Poon0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 2 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
103000550
Date of Patent
May 28, 2019
0Patent Application Number
153029300
Date Filed
April 10, 2015
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 26 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10300055 Treatment of parkinson's disease through ARFGAP1 inhibition
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10300055
Date of patent
May 28, 2019
Patent application number
15302930
Date Filed
April 10, 2015
Patent primary examiner
Find more entities like US Patent 10300055 Treatment of parkinson's disease through ARFGAP1 inhibition
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.